SHAREHOLDERS' EQUITY - Narrative (Details)			3 Months Ended		9 Months Ended		70 Months Ended
	Jul. 18, 2021	Feb. 04, 2020 USD ($) sales_agent	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	May 21, 2024 USD ($)	May 20, 2024 USD ($)	Aug. 02, 2022 USD ($)	Aug. 01, 2022 USD ($)	Aug. 31, 2021 USD ($)	Jul. 28, 2021 USD ($)	May 26, 2021 USD ($)	Feb. 20, 2020	Mar. 04, 2019 USD ($)
Subsidiary or Equity Method Investee [Line Items]
Repurchase authorized amount												$ 20,000,000	$ 20,000,000
Restricted Stock | 2010 Plan
Subsidiary or Equity Method Investee [Line Items]
Right to grant period	10 years
Equity ATM Program
Subsidiary or Equity Method Investee [Line Items]
Maximum consideration threshold		$ 100,000,000.0						$ 1,000,000,000	$ 650,000,000	$ 650,000,000.0	$ 250,000,000.0			$ 250,000,000.0		$ 50,000,000.0
Number of additional sales agents | sales_agent		2
Gross sales commission percentage														1.50%	2.00%
Number of shares sold (in shares) | shares			2,364,147	3,036,234	4,702,227	6,663,692	30,048,664
Weighted average price per share (in usd per share) | $ / shares			$ 22.68	$ 21.92	$ 23.93	$ 20.25	$ 21.35
Gross proceeds received			$ 53,620,000	$ 66,549,000	$ 112,540,000	$ 134,965,000	$ 641,400,000
Net proceeds received			52,915,000	$ 65,551,000	110,951,000	$ 132,941,000	631,500,000
Available under the equity ATM program			$ 358,600,000		$ 358,600,000		$ 358,600,000